Comparison · NCT03640949-49e2069a
Vasopressin and Methylprednisolone vs Placebo: Number of Participants That Survived 30 Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vasopressin and Methylprednisolone vs Placebo: Number of Participants That Survived 30 Days. Trial comparisons, record NCT03640949-49e2069a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640949-49e2069a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.097 | 0.0655 | 0.141 | wilson | |
| Risk in group 2 | 0.117 | 0.084 | 0.162 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0204 | -0.0748 | 0.0352 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.826 | 0.496 | 1.38 | log | |
| Odds ratio, group 1 over group 2 | 0.808 | 0.457 | 1.43 | log | |
| Number needed to treat, for one fewer participant with the outcome on Vasopressin and Methylprednisolone than on Placebo | 49.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vasopressin and Methylprednisolone | The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).~Vasopressin, Arginine: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)~Methylprednisolone: 40 mg methylprednisolone once | 23 | 237 | OG000 |
| Group 2 | Placebo | The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.~NaCl: Placebo | 31 | 264 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants That Survived 30 Days
- Description
- Time frame
- At 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
- NCT number
- NCT03640949
- Phases
- PHASE2, PHASE3
- Conditions
- Heart Arrest
- Interventions
- Vasopressin, Arginine, Methylprednisolone, NaCl
- Lead sponsor
- Lars Wiuff Andersen
- Results first posted
- 2022-01-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03640949?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03640949-49e2069a